

Supplementary Materials: Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors

Salma El-Behaedi, Rebekah Landsman, Michael Rudloff, Emily Kolyvas, Rakan Albalawy, Xianyu Zhang, Tapan Bera, Keith Collins, Serguei Kozlov and Christine Alewine




Figure S1. Panc02-chiMSLN cell model. (A) Schema of chiMSLN construct. (B) WT Panc02 and Panc02-chiMSLN cells were treated with a concentration curve of LMB-100 and viability was assessed by colorimetric assay after 72 hours. (C) WT Panc02 and Panc02-chiMSLN cells were incubated with anti-hMSLN monoclonal antibodies that recognize chiMSLN (Morab009 or MN) followed by appropriate phycoerythrin-labeled secondary, then surface expression of chiMSLN was assessed by flow cytometry. (D) Viable Panc02-chiMSLN cells were counted 24 and 48 hours after initiation of LMB-100 treatment. (E) Panc02-chiMSLN cells were treated with LMB-100 or cycloheximide (positive control for protein synthesis inhibition) for 24hrs, pulse labeled with low dose puromycin, then lysed and immunoblotted with anti-puromycin antibody to assess for protein synthesis inhibition. Shown is representative blot of triplicate samples.